Euroscreen announces name change to Ogeda and completion of Series B financing

Gosselies, Belgium: 19 October 2016 - Euroscreen today became Ogeda. The new corporate identity, as Ogeda, reflects the Company's primary focus on the discovery and development of first-in-class small molecule drug candidates targeting G-Protein Coupled Receptors (GPCRs). Ogeda also launched a new corporate website that is accessible on: 

The launch of its new corporate brand follows the successful completion of the second and final tranche of the Company's EUR 18 million Series B financing, which was first announced in October 2015. The second tranche of funding was subject to the completion of clinical milestones with lead product ESN364, which is currently in three parallel Phase IIa trials for Menopausal Hot Flashes, PolyCystic Ovary Syndrome (PCOS) and Uterine Fibroids. All milestones were achieved ahead of schedule and the additional funds will be used to fully finance the ongoing clinical programs.

More info on Ogeda's website.

Next > Gene expression RNA-Seq data analysis becomes simpler with the collaboration of Lexogen and Bluebee.

Previous > NGDATA adds Didier Van der Coelden as Chief Financial Officer